Less Ads, More Data, More Tools Register for FREE

Pin to quick picksManolete Partn. Regulatory News (MANO)

Share Price Information for Manolete Partn. (MANO)

Share Price is delayed by 15 minutes
Get Live Data
39.00    1.00 (2.63%)
Bid:
38.00
Ask:
40.00
Spread: 2.00 (5.263%)
Market Cap: £17.09m
MANO Live PriceLast checked at - London Stock Exchange

Intraday Manolete Partn. Share Chart

Full Year Trading Update

24 Apr 2026 07:00

RNS Number : 7350B
Manolete Partners PLC
24 April 2026
 

24 April 2026

 

Manolete Partners PLC

("Manolete" or the "Company")

 

Full Year Trading Update

 

Strong H2 trading performance as forecast

 

Manolete, the UK's leading insolvency claims financing company, today announces a trading update for the year ended 31 March 2026 ("FY26"). All figures in this announcement remain subject to audit.

 

Highlights

 

· Strong H2 trading performance

· FY26 Realised Revenue of c.£28.0m (FY25: £29.5m) in line with expectations

· Strong gross cash receipts of £26.6m (FY25: £25.6m)

· Net Debt of £11.5m (FY25: £11.1m) and free cash outflow of £0.2m (FY25: inflow of £0.5m)

· Forward book1 increased significantly in value to £67m (FY25: £49m) which provides confidence for increased revenue and profits in FY27

 

FY26 trading performance

 

The Company is pleased to announce that Realised Revenue for the full year is expected to be in line with expectations2 at c.£28.0m (FY25: £29.5m). This reflects an increase in the number of higher value, higher margin case completions during the second half, as forecast.

 

Gross cash receipts were strong at £26.6m and represent a £1.0m increase versus the prior year. Net debt at 31 March 2026 increased to £11.5m (FY25: 11.1m) and there was a free cash outflow of £0.2m in the period (FY25: inflow of £0.5m).

 

The stronger trading performance in the second half enabled continued investment in new cases and helped offset one-off adjusting items3 and the non-payment by a small number of large debtors as noted in the Company's statement of 16 September 2025. Two of these payments continue to be delayed and the Company's net exposure to these debtors is approximately £4.7m. The Board remains confident that the full amount will be received in due course. However, the Company has not yet concluded its bad debt review in conjunction with its auditors and if there is no change in circumstances before the conclusion of the audit, the Company will consider some provision against these debtors, which is likely to be in the region of £1.5m-£2.0m. The Company's expectation of Adjusted Realised Profit Before Tax (PBT)3 is £1.9m (FY25: £0.6m) before any adjustment for these debtors.

 

Good progress on strategic initiatives

 

During the year, the Company made good progress in further strengthening its operations to provide a platform for continued growth whilst maintaining focus on its highly efficient system of working.

 

The Company made three new hires into the legal team to drive continued growth in the number of new case referrals and implemented new business development initiatives to support the Company's existing nationwide referral network. This has led to £32m of new cases being signed in FY26 (FY25: £26m), representing a 23% increase year-on-year, and this is expected to increase further during FY27 as the enlarged team continues to drive new case signings at higher levels of volume and value.

 

In relation to the Company's loan facility, HSBC has waived the requirement for former CEO Steven Cooklin to maintain a minimum shareholding in the Company.

 

Refreshed leadership team and Board

 

During the year, the Company refreshed its leadership team, with Manolete's Managing Director Mena Halton appointed as Chief Executive Officer in August 2025 and highly experienced public markets CFO Will Sawyer appointed as Chief Financial Officer in December 2025.

 

The Company also welcomed leading barrister Marcia Shekerdemian KC to the Board as a Non-Executive Director in March 2026. She replaced Dr. Stephen Baister, who stepped down from the Board but continues to provide consultancy to the Company.

 

Outlook

 

The forward book at 31 March 2026 was £67m and has grown by £18m or 37% year-on-year. This has been driven by the investment in the legal team and business development initiatives which has resulted in higher value cases being signed. Large cases with a forecast revenue value over £0.5m comprise £32m of the forward book, up from £21m at prior year end.

 

Given the growth in the forward book and the backdrop of an improving insolvency market, the Board are confident of increasing Realised Revenue and Realised PBT in FY27.

 

Commenting, Mena Halton, Chief Executive Officer said:

 

"We performed well in the second half, with an increase in the number of higher value case completions driving improved trading performance, as we forecast at the half year. At the same time, we continued to strengthen our team and new business development function to support our future growth. Our forward book has increased significantly in value and we are confident of continuing to build on our market leadership position as UK insolvencies persist at elevated levels."

 

 

1. The value of the forward book represents the aggregate forecast revenue on live cases excluding cartel cases.

2. Company compiled consensus prior to the release of this announcement for the year ended 31 March 2026: Realised Revenue £28.3m and Realised Profit Before Tax £1.5m.

3. Adjusted Realised Profit Before Tax is defined as Realised Profit Before Tax before Adjusting Items comprising reorganisation and restructuring costs and share based payment charges totalling £1.2m.

 

 

The information contained in this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement this inside information is now considered to be in the public domain.

 

 

For further information please contact:

 

Manolete Partners

Mena Halton (Chief Executive Officer) via Houston

Will Sawyer (Chief Financial Officer)

 

Canaccord (NOMAD and Sole Broker) +44 (0)20 7523 8000

Stuart Andrews

Emma Gabriel

Harry Rees

 

Houston (Financial PR) +44 (0)77 3303 2695

Charlie Barker +44 (0)20 4529 0549

Nick Jackman

Manolete@houston.co.uk

 

About Manolete Partners PLC

Manolete Partners Plc is the UK's leading insolvency claims financing company. Serving a growing market worth over £500 million annually, the Company has a highly experienced team with coverage across the UK and a proven track record of generating strong historic returns across over 1,400 cases financed and completed to date.

 

Widely recognised as the industry leader, Manolete is the only company in the insolvency litigation funding section to be ranked in Band 1 of the legal industry's prestigious Chambers Guide five times. The Company is also five-time winner of 'Insolvency Litigation Funder of the Year' at the Turnaround, Restructuring and Insolvency Industry Awards.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOSNRNBUSUAR
Date   Source Headline
1st Jun 20267:00 amRNSBlock Listing Six Monthly Return
20th May 202612:00 pmRNSDirectorate Change
28th Apr 20263:19 pmRNSHolding(s) in Company
24th Apr 20267:00 amRNSFull Year Trading Update
31st Mar 20267:00 amRNSDirectorate Changes
22nd Dec 20257:00 amRNSGrant of Share Options
22nd Dec 20257:00 amRNSGrant of Share Options
17th Dec 20253:13 pmRNSHolding(s) in Company
1st Dec 20257:00 amRNSBlock Listing Six Monthly Return
25th Nov 20257:00 amRNSDirector/PDMR Shareholding
21st Nov 20254:10 pmRNSHolding(s) in Company
19th Nov 20257:00 amRNSHalf-year results
4th Nov 20257:00 amRNSNotice of Interim Results
16th Sep 20252:41 pmRNSResult of AGM
16th Sep 20257:00 amRNSAGM Update
22nd Aug 20257:00 amRNSDirectorate Change
20th Aug 202512:11 pmRNSPosting of Annual Report and Notice of AGM
11th Aug 20257:00 amRNSBoard Changes
5th Aug 202510:18 amRNSHolding(s) in Company
5th Aug 202510:17 amRNSHolding(s) in Company
1st Aug 20257:00 amRNSTotal Voting Rights
28th Jul 20258:30 amRNSHolding(s) in Company
21st Jul 20257:00 amRNSTruck Cartel Case Settlement
14th Jul 20257:00 amRNS-RMelloMonday Investor Webinar
9th Jul 20251:45 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNSFull Year Results
25th Jun 20257:00 amRNS-RManolete ranked in Band 1 by Chambers
19th Jun 20252:45 pmRNSHolding(s) in Company
19th Jun 20251:54 pmRNSNotice of Results
30th May 20257:00 amRNSBlock Listing Six Monthly Return
29th Apr 20257:00 amRNSTrading Update
7th Apr 202512:41 pmRNSDirectorate Change
28th Mar 20257:00 amRNSNew Revolving Credit Facility with HSBC Bank
4th Feb 20257:00 amRNSUpdate on Cartel Claims
29th Nov 20247:00 amRNSBlock Listing Six Monthly Return
19th Nov 20247:00 amRNSHalf-year Report
24th Oct 20241:49 pmRNSNotice of Results
17th Oct 202412:35 pmRNSDirector/PDMR Shareholding
30th Sep 202411:49 amRNSResult of AGM
20th Sep 20247:00 amRNSGrant of Share Options
6th Sep 20241:41 pmRNSPosting of Annual Report and Notice of AGM
3rd Sep 20247:00 amRNSAudited results for the year ended 31 March 2024
29th Aug 20247:00 amRNSRetail Investor Presentation
25th Jul 20245:09 pmRNSPCA Shareholding
27th Jun 20247:00 amRNSNotice of Results
31st May 20247:00 amRNSBlock Listing Six Monthly Return
8th May 20247:00 amRNSAppointment of New External Audit Firm
2nd May 20247:00 amRNSChange of Auditor
18th Apr 20247:00 amRNSTrading and Business Update
26th Feb 20247:00 amRNSAppointment of Nominated Adviser and Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.